Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab Soravtansine in Platinum-resistant Ovarian Cancer
NCT06682988Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial of mirvetuximab soravtansine in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (3 cohorts), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants with Grade >= 2 Treatment-Emergent Corneal Adverse Events, Objective Response Rate and 6 more. Started May 2025; status: recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT06682988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682988.